Health Condition 1: M109- Gout, unspecified
Conditions
Interventions
Intervention1: Joshanda (Decoction): It is classical Unani formulation taken from Guna Muna written by Al Qamri Abu Al Mansoor ul Hasan. The formulation comprises of two drugs namely Suranjan shirin (
Sponsors
Central Council for Research in Unani Medicine CCRUM New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients in between the age group of 18-60 years. 2) Patients irrespective of gender. 3) Patients with increased serum uric acid level more than 7.0 mg/dl in males and more than 6.0 mg/dl in females with clinical features of Gout. 4) Patients with Joint Pain. 5) Patients with swelling of the affected joint(s). 6) Patients with restricted movement of the joint(s). 7) Patients willing to sign informed consent, follow the protocol and willing to participate in the clinical study voluntarily.
Exclusion criteria
Exclusion criteria: 1) Pregnant and lactating women. 2) Known cases of renal, cardiac, liver and pulmonary system dysfunctions. 3) Patients suffering from Diabetes Mellitus. 4) Poorly controlled Hypertension i.e., Blood Pressure more than 160/100. 5) Patients of gout suffering from severe anemia, and other blood dyscrasias like leukemia or haemophilia. 6) Patients of gout associated with any severe arthritic condition such as rheumatoid arthritis or septic arthritis. 7) Patients with a history of congenital gout. 8) Patients undergoing chemotherapy for cancer treatment. 9) Patients taking thiazide group of diuretics, low-dose aspirin, or NSAIDs. 10) Patients who refuse to give the written consent for the study and who refuse to attend scheduled follow up as specified in the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Serum Uric Acid at baseline and at the end of the treatment. Timepoint: 29 Days | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in the subjective parameters on each Follow Up (0 day, 14 day & 29 day). Reduction in C-Reactive Proteins (CRP) & Erythrocytic Sedimentation Rate (ESR) at baseline and at the end of the treatment. Gout Impact Scale at baseline and at the end of the treatment. Timepoint: 29 Days | — |
Countries
India
Contacts
Public ContactSahiba
Regional Research Institute of Unani Medicine, Srinagar
Outcome results
None listed